MOS Prebiotic for Gut Health in Healthy Older Adults

Overseen By Melissa Moreno, BS

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: University of Florida

Must not be taking: Antibiotics, Laxatives, Antidiarrheals

Disqualifiers: Yeast allergy, Kidney disease, Intestinal disease, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 3 weeks

40 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

Mannooligosaccharides (MOS) derived from baker's yeast may have prebiotic properties such as improving gastrointestinal function. The aims of this study are to determine the effect of MOS on gastrointestinal function and symptoms and fecal microbiota in older adults.

Will I have to stop taking my current medications?

The trial requires that you stop using antibiotics, laxatives, and antidiarrheal medications before participating. If you are using any of these, you will need to stop them to be eligible for the study.

Is Mannooligosaccharides (MOS) safe for human consumption?

While specific safety data for Mannooligosaccharides (MOS) is not provided, similar prebiotics like xylooligosaccharide (XOS) have been shown to be well-tolerated without significant gastrointestinal side effects in healthy adults. ^{1 2 3 4 5}

How does the MOS prebiotic treatment for gut health in healthy older adults differ from other treatments?

The MOS prebiotic treatment is unique because it specifically targets gut health by enhancing the diversity of beneficial gut bacteria, which is particularly important for older adults. Unlike other treatments, MOS focuses on modulating the gut microbiota composition, potentially improving overall gut health and resilience in this age group. ^{6 7 8 9 10}

What data supports the effectiveness of the treatment Mannooligosaccharides for gut health in healthy older adults?

Research on similar prebiotics like galacto-oligosaccharides (GOS) shows they can increase beneficial gut bacteria, such as bifidobacteria, in older adults, which may help improve gut health. ^{1 6 11 12 13}

Are You a Good Fit for This Trial?

This trial is for healthy older adults aged 60-99 who can consent in English and are willing to follow the study procedures. It's not suitable for those with kidney disease, gastrointestinal surgeries or conditions, yeast allergies, current cancer treatment, recent antibiotic use, or if they're taking certain medications like laxatives.

Inclusion Criteria

Willingness to complete all study procedures

Able to provide written informed consent in English

I am between 50 and 99 years old.

Exclusion Criteria

Use of other investigational products within 3 months of the screening visit

I am currently taking medication for constipation or diarrhea.

I have had surgery on my digestive system.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive 15 g per day of yeast-derived mannooligosaccharides to evaluate effects on gastrointestinal symptoms, stool frequency, fecal microbiome, and urinary metabolites

3 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

2 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Mannooligosaccharides

Trial Overview The study is testing whether a yeast extract called Mannooligosaccharides (MOS) has prebiotic benefits that could improve gut function and alter fecal microbiota in older adults.

How Is the Trial Designed?

Group I: Mannooligosaccharides Experimental Treatment 1 Intervention

Mannooligosaccharides yeast extract

Who Is Running the Clinical Trial?

University of Florida

Lead Sponsor

Trials

1,428

Recruited

987,000+

Lallemand Bio-Ingredients

Collaborator

Trials

4

Recruited

110+

Published Research Related to This Trial

In a study involving 30 obese women over 3 months, treatment with inulin-type fructans (ITF prebiotics) significantly altered gut microbiota composition, increasing beneficial bacteria like Bifidobacterium and Faecalibacterium prausnitzii, which are linked to lower serum lipopolysaccharide levels.

The ITF prebiotics also resulted in a slight decrease in fat mass and changes in plasma metabolites, suggesting that these prebiotics can modestly influence host metabolism and may have implications for obesity and diabetes management.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Dewulf, EM., Cani, PD., Claus, SP., et al.[2022]

In a study using fecal cultures from healthy and morbidly obese adults, different prebiotics were tested, revealing that 1-kestose had the most significant impact on gut microbiota composition and metabolic activity.

Prebiotic modulation led to increased Bacteroides and Faecalibacterium in obese individuals, while normal-weight individuals showed higher levels of Bifidobacterium and Faecalibacterium, highlighting the need for tailored prebiotic treatments based on individual microbiota profiles.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

In Vitro Evaluation of Different Prebiotics on the Modulation of Gut Microbiota Composition and Function in Morbid Obese and Normal-Weight Subjects. Nogacka, AM., Salazar, N., Arboleya, S., et al.[2023]

Citations

1. England pubmed.ncbi.nlm.nih.gov

Galacto-oligosaccharides supplementation in prefrail older and healthy adults increased faecal bifidobacteria, but did not impact immune function and oxidative stress. [2021]

2. England pubmed.ncbi.nlm.nih.gov

The pleiotropic effects of prebiotic galacto-oligosaccharides on the aging gut. [2022]

3. France pubmed.ncbi.nlm.nih.gov

Systemic inflammatory markers in older persons: the effect of oral nutritional supplementation with prebiotics. [2014]

4. England pubmed.ncbi.nlm.nih.gov

A randomised crossover study investigating the effects of galacto-oligosaccharides on the faecal microbiota in men and women over 50 years of age. [2013]

5. England pubmed.ncbi.nlm.nih.gov

Influence of galacto-oligosaccharide mixture (B-GOS) on gut microbiota, immune parameters and metabonomics in elderly persons. [2022]

6. England pubmed.ncbi.nlm.nih.gov

In vitro measurement of the impact of human milk oligosaccharides on the faecal microbiota of weaned formula-fed infants compared to a mixture of prebiotic fructooligosaccharides and galactooligosaccharides. [2018]

7. England pubmed.ncbi.nlm.nih.gov

Xylooligosaccharide increases bifidobacteria but not lactobacilli in human gut microbiota. [2014]

8. England pubmed.ncbi.nlm.nih.gov

Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. [2022]

9. United States pubmed.ncbi.nlm.nih.gov

Effects of isomalto-oligosaccharides on bowel functions and indicators of nutritional status in constipated elderly men. [2019]

10. Canada pubmed.ncbi.nlm.nih.gov

Changes of the mice intestinal microbes by the oligosaccharides-enriched fermented milk in a gender-dependent pattern. [2021]

11. United States pubmed.ncbi.nlm.nih.gov

Potential of High- and Low-Acetylated Galactoglucomannooligosaccharides as Modulators of the Microbiota Composition and Their Activity: A Comparison Using the In Vitro Model of the Human Colon TIM-2. [2021]

12. England pubmed.ncbi.nlm.nih.gov

Prebiotic effects of pectooligosaccharides obtained from lemon peel on the microbiota from elderly donors using an in vitro continuous colon model (TIM-2). [2021]

13. Switzerland pubmed.ncbi.nlm.nih.gov

In Vitro Evaluation of Different Prebiotics on the Modulation of Gut Microbiota Composition and Function in Morbid Obese and Normal-Weight Subjects. [2023]